Search Patents
  • Publication number: 20240261392
    Abstract: A composition for increasing an immune response to a coronavirus may contain a coronavirus ORF8 protein, an immunogenic fragment of a coronavirus ORF8 protein, a nucleic acid encoding a coronavirus ORF8 protein, or immunogenic fragment of a coronavirus ORF8 protein. A method for increasing an immune response to a coronavirus may involve administering a composition containing a coronavirus ORF8 protein, an immunogenic fragment of a coronavirus ORF8 protein, a nucleic acid encoding a coronavirus ORF8 protein, or immunogenic fragment of a coronavirus ORF8 protein to a subject. Administration of an ORF8 composition may induce an immune response to the ORF8 protein or immunogenic fragment in the subject and may enhance the immune response of the subject to subsequent a coronavirus infection.
    Type: Application
    Filed: July 8, 2022
    Publication date: August 8, 2024
    Inventor: Steven C. QUAY
  • Publication number: 20250093335
    Abstract: Provided is a method for evaluating a severity risk of a coronavirus infectious disease. The method includes: (a) a step of bringing a subject-derived T cell into contact with a protein or fragment thereof derived from another kind of coronavirus which is a different kind of coronavirus from a causal virus of the coronavirus infectious disease; and (b) a step of evaluating a severity risk of the coronavirus infectious disease based on responsiveness of the T cell to the protein or fragment thereof. Also provided is a kit for evaluating a severity risk of a coronavirus infectious disease including a protein or fragment thereof derived from another kind of coronavirus which is a different kind of coronavirus from the causal virus of the coronavirus infectious disease.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 20, 2025
    Inventor: Tsutomu TAMADA
  • Publication number: 20230160895
    Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).
    Type: Application
    Filed: June 18, 2021
    Publication date: May 25, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
  • Publication number: 20230095701
    Abstract: Use of albiflorin or a pharmaceutically acceptable salt thereof or an extract or a pharmaceutical composition containing albiflorin in the preparation of a medicament for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia, or use thereof in the preparation of a medicament for treating prolonged symptoms of novel coronavirus pneumonia, performing rehabilitation conditioning after recovery of novel coronavirus pneumonia, or alleviating a possible sequela of novel coronavirus pneumonia, the sequela being depression, anxiety, sleep disorder, pain, palpitation, asthma, intestinal function disorder, or chronic fatigue syndrome. Albiflorin has the effects of anti-coronavirus, anti-inflammatory, inflammatory storm inhibition, human microecological balance regulation, etc.
    Type: Application
    Filed: September 25, 2020
    Publication date: March 30, 2023
    Inventor: Zuoguang Zhang
  • Publication number: 20220168243
    Abstract: Methods for the inhibition and antiviral treatment and prevention of coronavirus infections and particularly coronavirus antiviral therapies for the inhibition of coronavirus or treatment or prevention of coronavirus diseases in humans and animals by administering to a human or animal suffering from coronavirus infection, an effective amount of one or more specifically identified antiviral compounds that inhibit coronavirus infection or replication.
    Type: Application
    Filed: December 1, 2021
    Publication date: June 2, 2022
    Inventors: Ram Samudrala, Zackary Falls, William Mangione
  • Publication number: 20230391853
    Abstract: An antibody against a novel coronavirus, and a reagent and a kit for detecting the novel coronavirus, which relate to the technical field of antibodies. The antibody against the novel coronavirus includes a heavy chain complementarity determinant region and a light chain complementarity determinant region. The antibody has good affinity for N protein of the novel coronavirus, and has good sensitivity and specificity for detecting the novel coronavirus. Antibody options are provided for detection of the novel coronavirus.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 7, 2023
    Inventors: Peng CUI, Zhiqiang HE, Yuan MENG, Dongmei ZHONG, Wenjuan LOU, Lingyun FAN
  • Publication number: 20220144939
    Abstract: Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.
    Type: Application
    Filed: October 14, 2021
    Publication date: May 12, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson RUIZ-OPAZO, Victoria HERRERA
  • Publication number: 20210388032
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: July 28, 2021
    Publication date: December 16, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Thedorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • Publication number: 20220323533
    Abstract: The present disclosure relates to a composition for preventing, inhibiting or treating coronavirus infection, including an effective amount of camellia saponin. The camellia saponin may be extracted from oil press cake of camellia, and the coronavirus may be severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The composition according to the present disclosure can effectively prevent or inhibit or treat the coronavirus infection by inhibiting the activity of coronavirus without side effects. In addition, the composition according to the present disclosure can inhibit the penetration of the coronavirus into the human body by eliminating the coronavirus remaining on the skin.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Hyunjung CHOI, Jaeyoung KO, Yonghee LEE, Hyoung June KIM, Wonseok PARK, Heungsoo BAEK
  • Publication number: 20210246170
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: August 12, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • Publication number: 20230075527
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: March 9, 2023
    Inventors: Dan H. BAROUCH, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, An VANDEBOSCH, Mathieu Claude Michel LE GARS, Jerald C. SADOFF
  • Publication number: 20240226279
    Abstract: Disclosed are compositions related to modified coronavirus S protein peptides, synthetic coronavirus S protein peptides, chimeric coronavirus S protein peptides, anti-coronavirus S protein antibodies and methods of treating coronavirus infections using said peptides or antibodies.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 11, 2024
    Inventor: Pravin T.P. Kaumaya
  • Patent number: 11584792
    Abstract: Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: February 21, 2023
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria Herrera
  • Publication number: 20190202868
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 11384122
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
  • Publication number: 20230374452
    Abstract: The present invention provides human cells that can be stably infected with coronavirus, as human cells for research on infection with coronavirus such as SARS-CoV-2, as well as, by utilizing the cells, a method for confirming the presence of a coronavirus in a sample, a method for producing a coronavirus, and a method for evaluating the presence or absence of anti-coronavirus activity of a test sample or a substance having an anti-coronavirus neutralizing action in a test sample. Specifically, the present invention relates to a method for preparing a coronavirus-infectious immortalized human myeloid cell, including introducing ACE2 and TMPRSS2 into an immortalized human myeloid cell, and the like.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Inventors: Jun Shimizu, Naomi Tanga, Misuzu Yamada, Kazuo Miyazaki, Tatsuo Shioda, Emi Nakayama, Tadahiro Sasaki, Ritsuko Koketsu
  • Publication number: 20240352022
    Abstract: The present invention relates to a group of IMB-C5 series compounds having anti-coronavirus activity and the application thereof. The structure of the IMB-C5 series compounds is as shown in formula (1). The application is an application of the IMB-C5 series compounds in preparing a drug. The drug is a drug for inhibiting coronavirus, and is preferably a drug for treating human coronavirus infection. The coronavirus is preferably human ?-coronavirus or human ?-coronavirus, especially novel coronavirus (SARS-COV-2).
    Type: Application
    Filed: June 16, 2022
    Publication date: October 24, 2024
    Inventors: Bin HONG, Xiaofang CHEN, Yu DU, Yuhuan LI, Xiaotian DING, Mengqian QIAO, Yihua LI, Kun WANG, Cong BIAN, Haiyan YAN, Shuo WU, Huiqiang WANG, Rongmei GAO, Li WANG, Lifei WANG, Hongmin SUN, Xingxing LI
  • Publication number: 20230149534
    Abstract: The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: David Berd, James Passin
  • Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • Publication number: 20220401519
    Abstract: Disclosed are a use of an interferon in preparing a drug for preventing novel coronavirus SARS-CoV-2 infection or a disease COVID-19 caused by the novel coronavirus infection, and a drug for preventing novel coronavirus infection or preventing a disease COVID-19 caused by the novel coronavirus infection.
    Type: Application
    Filed: August 21, 2022
    Publication date: December 22, 2022
    Inventors: Zhongji MENG, Hai LI
Narrow Results

Filter by US Classification